Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 349-361

  Wang, Xiao Qin ^a,b   Xia, Chun Li ^a   Chen, Shuo Bin ^a   Tan, Jia Heng ^a   Ou, Tian Miao ^a   Huang, Shi Liang ^a   Li, Ding ^a   Gu, Lian Quan ^a   Huang, Zhi Shu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

2 Arylethenylquinoline derivatives; Alzheimer's disease; Antioxidant; A aggregation; Metal chelating

Indexed keywords

4 (4 METHOXYANILINO) 2 (4 DIETHYLAMINO STYRYL)QUINOLINE; 4 (4 METHOXYANILINO) 2 (4 DIMETHYLAMINO STYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (2 METHOXYSTYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 CHLOROSTYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 DIETHYLAMINO STYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 DIMETHYLAMINO STYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 FLUOROSTYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 METHOXYSTYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 (4 NITROSTYRYL)QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 STYRYL QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 [(1H INDOL 3 YL)ETHENYL]QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 [(9 ETHYL 9H CARBAZOL 3YL)ETHENYL]QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 [4 (METHYLPIPERAZIN 1 YL)STYRYL]QUINOLINE; 4 (4 METHYLPIPERAZIN 1 YL) 2 [4 (MORPHOLIN 1 YL)STYRYL]QUINOLINE; 4 (PIPERID 1 YL) 2 (4 NITROSTYRYL)QUINOLINE; 4 (PIPERID 1 YL) 2 [(9 ETHYL 9H CARBAZOL 3 YL)ETHENYL]QUINOLINE; 4 PIPERIDYL 2 (2 METHOXYSTYRYL)QUINOLINE; 4 PIPERIDYL 2 (4 CHLOROSTYRYL)QUINOLINE; 4 PIPERIDYL 2 (4 DIETHYLAMINO STYRYL)QUINOLINE; 4 PIPERIDYL 2 (4 DIMETHYLAMINO STYRYL)QUINOLINE; 4 PIPERIDYL 2 (4 METHOXYSTYRYL)QUINOLINE; 4 PIPERIDYL 2 (4 MORPHOLIN 1 YL STYRYL)QUINOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; CHELATING AGENT; CHOLINESTERASE; QUINOLINE DERIVATIVE; TROLOX C; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CHOLINESTERASE INHIBITOR; PEPTIDE FRAGMENT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN AGGREGATION; STRUCTURE ACTIVITY RELATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; CELL LINE, TUMOR; CELL SURVIVAL; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; QUINOLINES; STILBENES;

EID: 84928630909     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.018     Document Type: Article

References (61)

1. H. Forstl, A. Kurz, Clinical features of Alzheimer's disease, Eur. Arch. Psychiatry Clin. N. 249 (1999) 288-290.
2. V.H. Finder, Alzheimer's disease: a general introduction and pathomechanism, J. Alzheimers Dis. 22 (2010) 5-19.
3. E.D. Roberson, L. Mucke, 100 years and counting: prospects for defeating Alzheimer's disease, Science 314 (2006) 781-784.
4. V. Tumiatti, A. Minarini, M.L. Bolognesi, A. Milelli, M. Rosini, C. Melchiorre, Tacrine derivatives and Alzheimer's disease, Curr. Med. Chem. 17 (2010) 1825-1838.
5. H.W. Querfurth, F.M. LaFerla, Alzheimer's disease, N. Engl. J. Med. 362 (2010) 329-344.
6. G. Pepeu, M.G. Giovannini, Cholinesterase inhibitors and beyond, Curr. Alzheimer Res. 6 (2009) 86-96.
7. A.V. Terry, J.J. Buccafusco, The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development, J. Pharmacol. Exp. Ther. 306 (2003) 821-827.
8. J. Hardy, The amyloid hypothesis for Alzheimer's disease: a critical reappraisal, J. Neurochem. 110 (2009) 1129-1134.
9. D.J. Selkoe, Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399 (1999) A23-A31.
10. J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 (2002) 353-356.
11. 1-40using (19) F NMR, Biochemistry 52 (2013) 1903-1912.
12. K. Ono, K. Hasegawa, H. Naiki, M. Yamada, Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro, Neurosci. Res. 75 (2004) 742-750.
13. J.H. Byun, H. Kim, Y. Kim, I. Mook-Jung, D.J. Kim, W.K. Lee, K.H. Yoo, Aminostyrylbenzofuran derivatives as potent inhibitors for Abeta fibril formation, Bioorg. Med. Chem. Lett. 18 (2008) 5591-5593.
14. S.R. Byeon, J.H. Lee, J.H. Sohn, D.C. Kim, K.J. Shin, K.H. Yoo, I. Mook-Jung, W.K. Lee, D.J. Kim, Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation, Bioorg. Med. Chem. Lett. 17 (2007) 1466-1470.
15. R. Narlawar, K. Baumann, R. Schubenel, B. Schmidt, Curcumin derivatives inhibit or modulate beta-amyloid precursor protein metabolism, Neurodegener. Dis. 4 (2007) 88-93.
16. T. Mohamed, W. Osmana, G. Tina, P.P. Raoa, Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations, Bioorg. Med. Chem. Lett. 23 (2013) 4336-4341.
17. A. Musial, M. Bajda, B. Malawska, Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment, Curr. Med. Chem. 14 (2007) 2654-2679.
18. E. Giacobini, Invited review: cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications, Neurochem. Int. 32 (1998) 413-419.
19. B. Ibach, E. Haen, Acetylcholinesterase inhibition in Alzheimer's disease, Curr. Pharm. Des. 10 (2004) 231-251.
20. D. Karlsson, A. Fallarero, G. Brunhofer, C. Mayer, O. Prakash, C.G. Mohan, et al., The exploration of thienothiazines as selective butyrylcholinesterase inhibitors, Eur. J. Pharm. Sci. 47 (2012) 190-205.
21. S. Darvesh, M.K. Cash, G.A. Reid, E. Martin, A. Mitnitski, C. Geula, Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APP SWE/PSEN1d-9 mouse model of alzheimer disease, J. Neuropathol. Exp. Neurol. 71 (2012) 2-14.
22. D.J. Bonda, X. Wang, G. Perry, A. Nunomura, M. Tabaton, X. Zhu, M.A. Smith, Oxidative stress in Alzheimer disease: a possibility for prevention, Neuropharmacology 59 (2010) 290-294.
23. R.B. Petersen, A. Nunomura, H.G. Lee, G. Casadesus, G. Perry, M.A. Smith, X. Zhu, Signal transduction cascades associated with oxidative stress in Alzheimer's disease, J. Alzheimers Dis. 11 (2007) 143-152.
24. D. Praticò, Oxidative stress hypothesis in Alzheimer's disease: a reappraisal, Trends Pharmacol. Sci. 29 (2008) 609-615.
25. A.I. Bush, Drug development based on the metals hypothesis of Alzheimer's disease, J. Alzheimers Dis. 15 (2008) 223-240.
26. P. Zatta, D. Drago, S. Bolognin, S.L. Sensi, Alzheimer's disease, metal ions and metal homeostatic therapy, Trends Pharmacol. Sci. 30 (2009) 346-355.
27. 2, J. Biol. Chem. 277 (2002) 40302-40308.
28. X. Huang, R.D. Moir, R.E. Tanzi, A.I. Bush, J.T. Rogers, Redox-active metals, oxidative stress, and Alzheimer's disease pathology, Ann. N. Y. Acad. Sci. 1012 (2004) 153-163.
29. D.R.C. McLachlan, T.P.A. Kruck, W. Kalow, D.F. Andrews, A.J. Dalton, M.Y. Bell, W.L. Smith, Intramuscular desferrioxamine in patients with Alzheimer's disease, Lancet 337 (1991) 1304-1308.
30. C.W. Ritchie, et al., Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial, Arch. Neurol. 60 (2003) 1685-1691.
31. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C.L. Masters, S. Targum, A.I. Bush, R. Murdoch, J. Wilson, C.W. Ritchie, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol. 7 (2008) 779-786.
32. A. Dedeoglu, K. Cormier, S. Payton, K.A. Tseitlin, J.N. Kremsky, L. Lai, X. Li, R.D. Moir, R.E. Tanzi, A.I. Bush, N.W. Kowall, J.T. Rogers, X. Huang, Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis, Exp. Gerontol. 39 (2004) 1641-1649.
33. M. Rosini, E. Simoni, A. Minarini, C. Melchiorre, Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces, Neurochem. Res. 39 (2014) 1914-1923.
34. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, C. Melchiorre, Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem. 51 (2008) 347-372.
35. S. Pervaiz, Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol, Drug Resist. Updates 7 (2004) 333-344.
36. J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence, Nat. Rev. Drug Discov. 5 (2006) 493-506.
37. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, M. Yamada, Potent anti-amyloidogenic and fibril-destabilizing effects of poly phenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease, J. Neurochem. 87 (2003) 172-181.
38. A.R.A. Ladiwala, J.C. Lin, S.S. Bale, A.M. Marcelino-Cruz, M. Bhattacharya, J.S. Dordick, P.M. Tessier, Resveratrol selectively remodels soluble oligomers and fibrils of amyloid aβ into off-pathway conformers, J. Biol. Chem. 285 (2010) 24228-24237.
39. J. Abraham, R.W. Johnson, Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice, Rejuvenation Res. 12 (2009) 445-453.
40. E. Fasano, S. Serini, N. Mondella, S. Trombino, L. Celleno, P. Lanza, A. Cittadini, G. Calviello, Antioxidant and anti-inflammatory effects of selected natural compounds contained in a dietary supplement on two human immortalized keratinocyte lines. Biomed. Res. Int., http://dx.doi.org/10.1155/2014/327452 (Epub 2014).
41. C.A. Oomen, E. Farkas, V. Roman, E.M.V. Beek, P.G. Luiten, P. Meerlo, Resveratrol preserves cerebrovascular density and cognitive function in aging mice, Front. Aging Neurosci. 1 (2009) 1-9.
42. J.M. Smoliga, J.A. Baur, H.A. Hausenblas, Resveratrol and health a comprehensive review of human clinical trials, Mol. Nutr. Food Res. 55 (2011) 1129-1141.
43. H.L. Wang, X.Y. Guo, S.D. Jiang, G.H. Tang, Automated synthesis of [18F]florbetaben as Alzheimer's disease imaging agent based on a synthesis module system, Appl. Radiat. Isotopes 71 (2013) 41-46.
44. 81F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging, J. Med. Chem. 55 (2012) 883-892.
45. H.F. Kung, C.W. Lee, Z.P. Zhuang, M.P. Kung, C. Hou, K. Plossl, Novel stilbenes as probes for amyloid plaques, J. Am. Chem. Soc. 123 (2001) 12740-12741.
46. S.E. Freeman, R.M. Dawson, Tacrine: a pharmacological review, Prog. Neurobiol. 36 (1991) 257-277.
47. A.M. Mancino, S.S. Hindo, A. Kochi, M.H. Lim, Effects of clioquinol on metaltriggered amyloid-β aggregation revisited, Inorg. Chem. 48 (2009) 9596-9598.
48. M. Oz, D.E. Lorke, G.A. Petroianu, Methylene blue and Alzheimer's disease, Biochem. Pharmacol. 78 (2009) 927-932.
49. H.L. Jiang, X. Wang, L. Huang, Z. Luo, T. Su, K. Ding, X. Li, Benzenediolberberine hybrids: multifunctional agents for Alzheimer's disease, Bioorg. Med. Chem. 19 (2011) 7228-7235.
50. P. Kapková, V. Alptüzün, P. Frey, E. Erciyas, U. Holzgrabe, Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity, Bioorg. Med. Chem. 14 (2006) 472-478.
51. Z.Q. Liu, S.T. Zhuo, J.H. Tan, T.M. Ou, D. Li, L.Q. Gu, Z.S. Huang, Facile syntheses of disubstituted bis(vinylquinolinium)benzene derivatives as G-quadruplex DNA binders, Tetrahedron 69 (2013) 4922-4932.
52. M. Bartolini, C. Bertucci, M.L. Bolognesi, A. Cavalli, C. Melchiorre, V. Andrisano, Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action, Chem BioChem 8 (2007) 2152-2161.
53. A. Davalos, C. Gómez-Cordoves, B. Bartolomě, Extending applicability of the oxygen radical absorbance capacity (ORAC-Fluorescein) assay, J. Agric. Food Chem. 52 (2003) 48-54.
54. Y. Oyama, A. Hayashi, T. Ueha, K. Maekawa, Y. Oyama, A. Hayashi, T. Ueha, K. Maekawa, Characterization of 2′,7′-dichloro-fluorescin fluorescence in dissociated mammalian brain neurons: estimation on intra cellular content of hydrogen peroxide, Brain Res. 635 (1994) 113-117.
55. M.L. Bolognesi, A. Cavalli, L. Valgimigli, M. Bartolini, M. Rosini, V. Andrisano, M. Recanatini, C. Melchiorre, Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease, J. Med. Chem. 50 (2007) 6446-6449.
56. G.L. Ellman, K.D. Courtney, V. Andres Jr., R.M. Feather-Stone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88-95.
57. 42 peptide, J. Am. Chem. Soc. 134 (2012) 6625-6636.
58. C.J. Lu, Y.Y. Guo, J. Yan, Z.H. Luo, H.B. Luo, M. Yan, L. Huang, X.S. Li, Design, synthesis, and evaluation of Multitarget-directed resveratrol derivatives for the treatment of alzheimer's disease, J. Med. Chem. 56 (2013) 5843-5859.
59. J.A. Lenhart, X. Ling, R. Gandhi, T.L. Guo, P.M. Gerk, D.H. Brunzell, S. Zhang, "Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization, J. Med. Chem. 53 (2010) 6198-6209.
60. M.L. Bolognesi, R. Banzi, M. Bartolini, A. Cavalli, A. Tarozzi, V. Andrisano, A. Minarini, M. Rosini, V. Tumiatti, C. Bergamini, R. Fato, G. Lenaz, P. Hrelia, A. Cattaneo, M. Recanatini, C. Melchiorre, Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease, J. Med. Chem. 50 (2007) 4882-4897.
61. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55-63.